ADMA News and Press, ADMA Biologics Inc From 01/19/24

2024-01-19 07:51:35 ET Summary ADMA Biologics enters 2024 on quite a roll and the stock should continue to do well going forward. The company has recently completed the build of its plasma collection network, turned the corner on profitability, and redid its credit facility in a p...

2024-01-08 12:32:21 ET More on ADMA Biologics ADMA Biologics: Achieving Important Inflection Points ADMA Biologics Q3 2023 Earnings Call Transcript ADMA Biologics refinances its credit facilities with Ares Management ADMA Biologics gets label expansion for Bi...

4Q 2023 Preliminary Unaudited Total Revenue of $72-74 Million FY 2023 Preliminary Unaudited Total Revenue of $256-258 Million FY 2024 and 2025 Total Revenue Guidance Increased to More than $320 Million and $370 Million, Respectively FY 2024 Net Income Expected to Exceed ...

2023-12-18 16:09:10 ET More on ADMA Biologics ADMA Biologics: Achieving Important Inflection Points ADMA Biologics gets label expansion for Bivigam in pediatric setting ADMA Biologics wins FDA nod for tenth plasma collection center Seeking Alpha’s Quan...

New $135 Million Credit Facility Replaces Existing $159 Million Credit Facility, a 15% Decrease in Total Debt Further Supports Rapid Q-o-Q and Y-o-Y Earnings Accretion RAMSEY, N.J. and BOCA RATON, Fla., Dec. 18, 2023 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“...

2023-12-12 07:51:01 ET ADMA Biologics ( NASDAQ: ADMA ) has received FDA approval for Bivigam for treating primary humoral immunodeficiency (PI) in patients aged 2 years and older. "This expanded label for Bivigam allows ADMA to actively address the treatment needs of younger...

Signifies the Successful Fulfillment of BIVIGAM’s Post Marketing Commitments as Part of the Original BLA Approval Expanded Label in the U.S. Now Includes Pediatric PI Patients 2 Years of Age and Older RAMSEY, N.J. and BOCA RATON, Fla., Dec. 12, 2023 (GLOBE NEWSWIRE) -- ADMA...

2023-11-17 18:29:00 ET Adma Biologics (NASDAQ: ADMA) finished the trading week on a high note, with its shares racing more than 4% higher in price on Friday. Investors were happy about the specialty healthcare company's latest news about its growing network of plasma-collection faci...

2023-11-16 07:37:44 ET More on ADMA Biologics ADMA Biologics: Achieving Important Inflection Points ADMA Biologics, Inc. (ADMA) Q3 2023 Earnings Call Transcript ADMA Biologics: From Plasma To Profits With A Pinch Of Prudence ADMA Biologics Q3 2023 Earnings Pr...

RAMSEY, N.J. and BOCA RATON, Fla. and LAUREL, Md., Nov. 16, 2023 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-...